ESC 365 - Introduction

ESC Premium Access

Introduction

Session: Evolving scientific evidence with PCSK9 inhibitors based on ODYSSEY outcomes

Topic: Cardiovascular Pharmacotherapy

Speaker: Professor J. Jukema (Leiden, NL)

Sponsored by Sanofi and Regeneron

Event: ESC Congress 2019

Congress Presentation

Add to my library

About the speaker

Professor J Wouter Jukema

Leiden University Medical Center, Leiden (Netherlands (The))

20 presentations

0 follower

5 more presentations in this session

The need for urgency in treating hyperlipidemia in post-ACS patients

Speaker: Professor F. Schiele (Besancon, FR)

Enriching the PCSK9i evidence - The most recent analyses from ODYSSEY OUTCOMES

Speaker: Professor J. Jukema (Leiden, NL)

Evaluating the benefit/risk and safety profile of PCSK9 inhibitors - Clinical and economic implications

Speaker: Doctor C. Ballantyne (Houston, US)

Panel discussion

Speaker: Professor J. Jukema (Leiden, NL) Professor F. Schiele (Besancon, FR) Doctor C. Ballantyne (Houston, US)

Conclusion and key takeaways

Speaker: Professor J. Jukema (Leiden, NL) Professor F. Schiele (Besancon, FR) Doctor C. Ballantyne (Houston, US)

Access the full session

Evolving scientific evidence with PCSK9 inhibitors based on ODYSSEY outcomes

Speakers: Professor J. Jukema, Professor F. Schiele, Professor J. Jukema, Doctor C. Ballantyne, Professor J. Jukema...

About the event

ESC Congress 2019

31 August - 4 September 2019

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources